leisure time -WSS

leisure time

author：explore 2025-10-01 13:59:16 - browse：34515

Kara Coluccio, a managing partner at Perspective Group poses for a portrait. -- health coverage from STAT — Kara Coluccio, a managing partner at Perspective Group, says the job market for biotech executives has gotten much tighter. Jessica Rinaldi/Globe Staff

When Crystal Shih Byers left her job at Novartis in 2020, she was excited to make the leap into a smaller startup.

Byers had spent almost nine years at Novartis, most recently helping lead a group that worked on gene therapy. But pharmaceutical companies are large and complex, and she craved more immediate impact. “I was looking for a place where I could be in the room,” she says. She wanted more autonomy, and to feel like her work would reach patients sooner.

At the time, biotech startups were rolling in cash and seeking to capture some of the magic that had fueled Moderna’s meteoric rise. They handed out lots of logo-embossed swag. “Investors were putting a lot of money into stupid science,” Byers says. “There were a lot of companies that lasted for a lot longer than I thought they would on very little data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： RaDonda Vaught links Vanderbilt hospital issues to patient death

focus

WSS

The nurse manager staffing crisis is hurting patients

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

New menopause drug shows promise in relief for hot flashes

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

How to save health care price transparency rules

Why scientists need input from humanists on sensitive research

Wikipedia

leisure time

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HHS names first

Wildfire smoke exposes gaps in outdoor worker protections

Health and fitness trackers are measuring the wrong things

DIEP, the 'gold standard' of breast reconstruction, is under threat

As AI in medicine takes off, can 'human in the loop' prevent harm?

Alkermes shareholders re

UCLA team creates talking throat patch for voice disorders

Psychedelics group wrestles with new pharma identity

Idaho abortion case may prompt more restrictions in other states

focus

HHS names first

HHS names first

WuXi out of biotech trade group, U.S. and China relations to blame

Three issues to watch in global health in 2024

GSK to buy asthma

JPM 2024: Nvidia claims we're in biological revolution. Are we?

focus

leisure time

focus

focus